Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.47154
Abstract: This cohort study investigates the association of hormone receptor status and first-line endocrine therapy with survival among patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–positive (ERBB2+ metastatic breast cancer. read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.48069
Abstract: This case series study provides an estimate of total cases of metastatic breast cancer in England based on National Health Service data. read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.2174
Abstract: This cohort study performs an external validation of a novel system for understanding outcomes of de novo metastatic breast cancer. read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.31722
Abstract: Key Points Question What is the association between detection of specific alterations in circulating tumor DNA (ctDNA) and survival in patients with metastatic breast cancer? Findings In this systematic review and meta-analysis reporting data from… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.57483
Abstract: This cohort study explores survival among patients with ERBB2-positive metastatic breast cancer with only central nervous system (CNS) metastasis compared with CNS and extracranial metastases. read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Advanced Healthcare Materials"
DOI: 10.1002/adhm.202202622
Abstract: Lung metastatic breast cancer (LMBC) is mainly diagnosed through CT imaging and radiotherapy could be the most common method in the clinic to inhibit tumor proliferation. While the sensitivity of radiotherapy is always limited due… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2453
Abstract: Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prognoses of patients with metastases… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3461
Abstract: Burdens related to time spent receiving cancer care may be substantial for patients with incurable, life‐limiting cancers such as metastatic breast cancer (MBC). Estimates of time spent on health care are needed to inform treatment‐related… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5369
Abstract: We analyzed the effect of statins in patients with hormone receptor‐positive (HR+) metastatic breast cancer treated with everolimus + exemestane (EverX). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5374
Abstract: The data on metastatic tumors to the pancreas diagnosed by fine needle aspiration (FNA) biopsy is limited. We report our experience of FNA of primary and secondary pancreatic tumors emphasizing metastatic breast cancer in the… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5885
Abstract: Little is known about the heterogeneous nature of financial hardship in younger patients with metastatic disease and the extent to which insurance protects against it. We examine the association between insurance status and multidimensional indicators… read more here.